Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study

Abstract

AimsTo investigate changes in glycated hemoglobin (HbA1c), body weight (BW), and systolic blood pressure (SBP) in type 2 diabetes (T2D) primary care patients initiating dapagliflozin treatment.MethodsT2D patients who started dapagliflozin in 985 general and 32 diabetologist practices (Disease Analyzer, Germany: December 2012–October 2014) were analyzed (3- and 6-month follow-up). Multivariate linear regression analyses were used to identify clinical characteristics and comorbidity associated with changes in HbA1c, BW, and SBP.ResultsThe study included 1,169 T2D patients (age: 62.5 years; men: 59.3%; diabetologist care: 23%) with newly initiated dapagliflozin therapy. At the 3-month stage, dapagliflozin significantly reduced HbA1c (−0.8%±1.4%) compared to the baseline (8.5%±1.5%) (P<0.001). Changes were maintained after 6 months (−0.8%±1.5%) (P<0.001). Patients with high baseline HbA1c values (>9%) showed greater reductions in HbA1c than the overall sample (3 months −1.8%, 6 months −1.8%; both P<0.05). BW and SBP also showed statistically significant reductions with dapagliflozin over 3 and 6 months (−2.2 kg, P<0.001; −2.2 mmHg, P=0.003 and −2.5 kg, P<0.001; −2.3 mmHg, P=0.011, respectively). After 3 months, 53% of patients achieved a reduction in both HbA1c and BW; the same holds true for 45% of patients at the 6-month mark. Similar results were observed both in general and diabetologist practices. In multivariate analyses, baseline HbA1c (parameter estimate: −0.6479) and diabetologist care (−0.2553) were independent predictors of HbA1c change (6 months) (all P<0.05).ConclusionT2D patients treated with dapagliflozin therapy achieved statistically significant reductions in HbA1c, BW, and SBP in a real-world primary and diabetologist care setting. The changes were comparable to the results of the dapagliflozin clinical trial program.

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

“…Body weight was reduced significantly in the dapagliflozin group. Hence, our data indicate an improved cardiovascular risk factor profile as previously described in detail in a real-world primary and diabetologist care setting [ 28 ] and also in the CVD-REAL Nordic study, where dapagliflozin treatment was associated with lower risk of cardiovascular events and all-cause mortality in type 2 diabetic patients compared to patients receiving dipeptidyl peptidase-4 inhibitor therapy [ 29 ].…”

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

“…With both doses of ertugliflozin, decreases in HbA1c were clinically relevant and consistent with reports for other SGLT2 inhibitors. 1,2,15 Treatment with ertugliflozin also resulted in significant improvements relative to placebo in other glycaemic measures,…”

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

“…Dapagliflozin exerts its glucose-lowering effects through inhibition of the SGLT2 protein in the kidney proximal tubule, resulting in the excretion of glucose and calories into the urine 8 ) . This negative energy balance results in dapagliflozin treatment-associated weight loss, as has been demonstrated in several clinical studies 9 – 11 ) . Diabetic patients frequently exhibit a progressive decline in muscle mass and impaired muscle functional quality 3 ) , which are caused by reduced insulin sensitivity and decreased mitochondrial function due to underlining pathogenesis of T2DM 12 ) .…”